Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL)

CAR-T cell therapy against CD19 has changed the treatment landscape in relapsed/refractory (r/r) B-ALL. R/r T-ALL has a dismal prognosis, with an unmet need for effective targeted therapies. Several unique challenges mean that CAR-T cell therapy has yet to be successfully translated to T-ALL. Most s...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.902-902
Hauptverfasser:	Maciocia, Nicola C, Burley, Amy, Nannini, Francesco, Wawrzyniecka, Patrycja, Neves, Margarida, Karpanasamy, Thaneswari, Ferrari, Mathieu, Marafioti, Teresa, Onuoha, Shimobi, Khwaja, Asim, Maciocia, Paul M, Pule, Martin
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!